Wegovy Maker Strikes $1B Deal for Next-Gen Obesity TreatmentNovo Nordisk acquires global rights to Lexicon's obesity drug LX9851, aiming to enhance its position in the obesity treatment market.
Novo Nordisk Just Bought the Next Big Thing in Weight LossNovo Nordisk secures global rights to Triple-G weight loss therapy through a licensing deal, targeting three hormones for better results.
CagriSema Fails to Meet Expectations in Late-Stage Obesity Trial, but Still Beats PlaceboNovo Nordisk's CagriSema obesity treatment underperformed in trials, showing lower weight loss than anticipated compared to Wegovy.
FDA Apporoves 'Alhemo' to Help Hemophilia Patients Manage BleedingNovo Nordisk's hemophilia treatment Alhemo has FDA approval, targeting patients with antibodies against traditional therapies.
Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese AdultsNovo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use...
Novo Nordisk Confirms Weight Loss Effects, New Blockbuster for Obesity TreatmentAnalysts have suggested that Novo Nordisk (NVO) could have another potential blockbuster obesity treatment following Semaglutide, along with the clinical results of Amycretin (Amylin/GLP dual receptor). Novo Nordisk’s stock price rose 9% on the day it announced the phase 1 clinical results of Amycretin. This product uses the same oral platform technology SNAC as applied […]
Must-Reads
1
Will Korea-China summit rekindle hopes of K-culture comeback in China?
LATEST
2
Workers may soon be able to ignore late-night work messages
LATEST
3
International matchmakers under scrutiny over consumer harm
LATEST
4
Nearly 25 Islamic State fighters killed or captured in Syria, US military says
LATEST
5
Hanwha Life wins ISO certification for AI security
Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment Novo Nordisk acquires global rights to Lexicon's obesity drug LX9851, aiming to enhance its position in the obesity treatment market.
Novo Nordisk Just Bought the Next Big Thing in Weight Loss Novo Nordisk secures global rights to Triple-G weight loss therapy through a licensing deal, targeting three hormones for better results.
CagriSema Fails to Meet Expectations in Late-Stage Obesity Trial, but Still Beats Placebo Novo Nordisk's CagriSema obesity treatment underperformed in trials, showing lower weight loss than anticipated compared to Wegovy.
FDA Apporoves 'Alhemo' to Help Hemophilia Patients Manage Bleeding Novo Nordisk's hemophilia treatment Alhemo has FDA approval, targeting patients with antibodies against traditional therapies.
Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese Adults Novo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use...
Novo Nordisk Confirms Weight Loss Effects, New Blockbuster for Obesity Treatment Analysts have suggested that Novo Nordisk (NVO) could have another potential blockbuster obesity treatment following Semaglutide, along with the clinical results of Amycretin (Amylin/GLP dual receptor). Novo Nordisk’s stock price rose 9% on the day it announced the phase 1 clinical results of Amycretin. This product uses the same oral platform technology SNAC as applied […]
Hot Topics